

Bart Hens

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4421151/publications.pdf>

Version: 2024-02-01

51
papers

1,870
citations

304743

22
h-index

265206

42
g-index

52
all docs

52
docs citations

52
times ranked

2216
citing authors

#	ARTICLE	IF	CITATIONS
1	Favipiravir at high doses has potent antiviral activity in SARS-CoV-2 ⁺ infected hamsters, whereas hydroxychloroquine lacks activity. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 26955-26965.	7.1	240
2	The mechanisms of pharmacokinetic food-drug interactions – A perspective from the UNGAP group. European Journal of Pharmaceutical Sciences, 2019, 134, 31-59.	4.0	224
3	A review of drug solubility in human intestinal fluids: Implications for the prediction of oral absorption. European Journal of Pharmaceutical Sciences, 2014, 57, 322-332.	4.0	159
4	Low Buffer Capacity and Alternating Motility along the Human Gastrointestinal Tract: Implications for <i>in Vivo</i> Dissolution and Absorption of Ionizable Drugs. Molecular Pharmaceutics, 2017, 14, 4281-4294.	4.6	94
5	Supersaturation and Precipitation of Posaconazole Upon Entry in the Upper Small Intestine in Humans. Journal of Pharmaceutical Sciences, 2016, 105, 2677-2684.	3.3	92
6	In vitro models for the prediction of in vivo performance of oral dosage forms: Recent progress from partnership through the IMI OrBiTo collaboration. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 136, 70-83.	4.3	91
7	Gastrointestinal behavior of nano- and microsized fenofibrate: In vivo evaluation in man and in vitro simulation by assessment of the permeation potential. European Journal of Pharmaceutical Sciences, 2015, 77, 40-47.	4.0	82
8	Exploring gastrointestinal variables affecting drug and formulation behavior: Methodologies, challenges and opportunities. International Journal of Pharmaceutics, 2017, 519, 79-97.	5.2	81
9	Persistent Threats by Persistent Pollutants: Chemical Nature, Concerns and Future Policy Regarding PCBs – What Are We Heading For?. Toxics, 2018, 6, 1.	3.7	68
10	Gastrointestinal transfer: In vivo evaluation and implementation in in vitro and in silico predictive tools. European Journal of Pharmaceutical Sciences, 2014, 63, 233-242.	4.0	63
11	<i>In Silico</i> Modeling Approach for the Evaluation of Gastrointestinal Dissolution, Supersaturation, and Precipitation of Posaconazole. Molecular Pharmaceutics, 2017, 14, 4321-4333.	4.6	59
12	Supersaturation in human gastric fluids. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 81, 184-189.	4.3	57
13	A Mechanistic Physiologically-Based Biopharmaceutics Modeling (PBBM) Approach to Assess the In Vivo Performance of an Orally Administered Drug Product: From IVVC to IVVP. Pharmaceutics, 2020, 12, 74.	4.5	49
14	Gastrointestinal and Systemic Monitoring of Posaconazole in Humans After Fasted and Fed State Administration of a Solid Dispersion. Journal of Pharmaceutical Sciences, 2016, 105, 2904-2912.	3.3	43
15	Evaluation and optimized selection of supersaturating drug delivery systems of posaconazole (BCS) Tj ETQq1 1 0.784314 rgBT /Overl... Journal of Pharmaceutical Sciences, 2018, 115, 258-269.	4.0	43
16	Formulation predictive dissolution (fPD) testing to advance oral drug product development: An introduction to the US FDA funded – 21st Century BA/BE –™ project. International Journal of Pharmaceutics, 2018, 548, 120-127.	5.2	41
17	Bile Salt Micelles and Phospholipid Vesicles Present in Simulated and Human Intestinal Fluids: Structural Analysis by Flow Field – Flow Fractionation/Multiangle Laser Light Scattering. Journal of Pharmaceutical Sciences, 2016, 105, 2832-2839.	3.3	36
18	Application of a Dynamic Fluid and pH Model to Simulate Intraluminal and Systemic Concentrations of a Weak Base in GastroPlus®, C. Journal of Pharmaceutical Sciences, 2019, 108, 305-315.	3.3	32

#	ARTICLE	IF	CITATIONS
19	In vitro evaluation of the impact of gastrointestinal transfer on luminal performance of commercially available products of posaconazole and itraconazole using BioGIT. <i>International Journal of Pharmaceutics</i> , 2016, 515, 352-358.	5.2	29
20	Drug disposition before and after gastric bypass: fenofibrate and posaconazole. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 1325-1332.	2.4	24
21	Gastric emptying and intestinal appearance of nonabsorbable drugs phenol red and paromomycin in human subjects: A multi-compartment stomach approach. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2018, 129, 162-174.	4.3	24
22	Mass Transport Analysis of the Enhanced Buffer Capacity of the Bicarbonate CO_2 Buffer in a Phase-Heterogenous System: Physiological and Pharmaceutical Significance. <i>Molecular Pharmaceutics</i> , 2018, 15, 5291-5301.	4.6	23
23	Linking the Gastrointestinal Behavior of Ibuprofen with the Systemic Exposure between and within Humans Part 1: Fasted State Conditions. <i>Molecular Pharmaceutics</i> , 2018, 15, 5454-5467.	4.6	21
24	Integrating Drug- and Formulation-Related Properties With Gastrointestinal Tract Variability Using a Product-Specific Particle Size Approach: Case Example Ibuprofen. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 3842-3847.	3.3	21
25	Measuring the Impact of Gastrointestinal Variables on the Systemic Outcome of Two Suspensions of Posaconazole by a PBPK Model. <i>AAPS Journal</i> , 2018, 20, 57.	4.4	19
26	Unraveling the behavior of oral drug products inside the human gastrointestinal tract using the aspiration technique: History, methodology and applications. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 155, 105517.	4.0	18
27	Exploring Bioequivalence of Dexketoprofen Trometamol Drug Products with the Gastrointestinal Simulator (GIS) and Precipitation Pathways Analyses. <i>Pharmaceutics</i> , 2019, 11, 122.	4.5	17
28	Linking the Gastrointestinal Behavior of Ibuprofen with the Systemic Exposure between and within Humans Part 2: Fed State. <i>Molecular Pharmaceutics</i> , 2018, 15, 5468-5478.	4.6	12
29	Evaluation of real-life dosing of oral medicines with respect to fluid and food intake in a Dutch-speaking population. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2017, 42, 467-474.	1.5	11
30	Exploring the impact of real-life dosing conditions on intraluminal and systemic concentrations of atazanavir in parallel with gastric motility recording in healthy subjects. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2020, 150, 66-76.	4.3	11
31	Using Physiologically Based Pharmacokinetic Modeling to Assess the Risks of Failing Bioequivalence Criteria: a Tale of Two Ibuprofen Products. <i>AAPS Journal</i> , 2020, 22, 113.	4.4	9
32	Dissolution Challenges Associated with the Surface pH of Drug Particles: Integration into Mechanistic Oral Absorption Modeling. <i>AAPS Journal</i> , 2022, 24, 17.	4.4	9
33	What can we learn from 'dioxin incidents'?. <i>International Journal of Environment and Pollution</i> , 2016, 60, 34.	0.2	8
34	Translational Modeling Strategies for Orally Administered Drug Products: Academic, Industrial and Regulatory Perspectives. <i>Pharmaceutical Research</i> , 2020, 37, 95.	3.5	8
35	Application of the Gastrointestinal Simulator (GIS) Coupled with In Silico Modeling to Measure the Impact of Coca-Cola® on the Luminal and Systemic Behavior of Loratadine (BCS Class 2b). <i>Pharmaceutics</i> , 2020, 12, 566.	4.5	8
36	Measurement of fasted state gastric antral motility before and after a standard bioavailability and bioequivalence 240 mL drink of water: Validation of MRI method against concomitant perfused manometry in healthy participants. <i>PLoS ONE</i> , 2020, 15, e0241441.	2.5	8

#	ARTICLE	IF	CITATIONS
37	“Development of Fixed Dose Combination Products” Workshop Report: Considerations of Gastrointestinal Physiology and Overall Development Strategy. AAPS Journal, 2019, 21, 75.	4.4	7
38	An In Vivo Predictive Dissolution Methodology (iPD Methodology) with a BCS Class IIb Drug Can Predict the In Vivo Bioequivalence Results: Etoricoxib Products. Pharmaceutics, 2021, 13, 507.	4.5	7
39	Biopredictive in vitro testing methods to assess intestinal drug absorption from supersaturating dosage forms. Journal of Drug Delivery Science and Technology, 2020, 56, 101275.	3.0	6
40	Mechanistic Deconvolution of Oral Absorption Model with Dynamic Gastrointestinal Fluid to Predict Regional Rate and Extent of GI Drug Dissolution. AAPS Journal, 2020, 22, 3.	4.4	6
41	Exploring the Predictive Power of the <i>In Situ</i> Perfusion Technique towards Drug Absorption: Theory, Practice, and Applications. Molecular Pharmaceutics, 2022, 19, 749-762.	4.6	3
42	Exploring the Impact of Intestinal Fluid Components on the Solubility and Supersaturation of Danazol. Journal of Pharmaceutical Sciences, 2021, 110, 2479-2488.	3.3	2
43	Leveraging Oral Drug Development to a Next Level: Impact of the IMI-Funded OrBiTo Project on Patient Healthcare. Frontiers in Medicine, 2021, 8, 480706.	2.6	2
44	Summary of the In Vivo Predictive Dissolution (iPD) - Oral Drug Delivery (ODD) Conference 2018. Dissolution Technologies, 2018, 25, 50-53.	0.6	2
45	What can we learn from 'dioxin incidents'?. International Journal of Environment and Pollution, 2016, 60, 34.	0.2	1
46	Title is missing!. , 2020, 15, e0241441.		0
47	Title is missing!. , 2020, 15, e0241441.		0
48	Title is missing!. , 2020, 15, e0241441.		0
49	Title is missing!. , 2020, 15, e0241441.		0
50	Title is missing!. , 2020, 15, e0241441.		0
51	Title is missing!. , 2020, 15, e0241441.		0